{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:18:50Z","timestamp":1767705530177},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12253-017-0240-4","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T11:43:02Z","timestamp":1493811782000},"page":"277-282","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary"],"prefix":"10.1007","volume":"24","author":[{"given":"Ahmed","family":"El-Balat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Schmeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Karn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"S\u00e4nger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Holtrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruza","family":"Arsenic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"issue":"20","key":"240_CR1","doi-asserted-by":"publisher","first-page":"7273","DOI":"10.1158\/1078-0432.CCR-05-0755","volume":"11","author":"IM Shih","year":"2005","unstructured":"Shih IM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11(20):7273\u20137279. doi: 10.1158\/1078-0432.CCR-05-0755","journal-title":"Clin Cancer Res"},{"issue":"8","key":"240_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ijc.23724","volume":"123","author":"I Skirnisdottir","year":"2008","unstructured":"Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008) Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 123(8):1897\u20131901. doi: 10.1002\/ijc.23724","journal-title":"Int J Cancer"},{"issue":"3","key":"240_CR3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/S1470-2045(11)70288-1","volume":"13","author":"P Morice","year":"2012","unstructured":"Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E (2012) Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 13(3):e103\u2013e115. doi: 10.1016\/S1470-2045(11)70288-1","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"240_CR4","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/modpathol.3800307","volume":"18","author":"WR Hart","year":"2005","unstructured":"Hart WR (2005) Borderline epithelial tumors of the ovary. Mod Pathol 18(Suppl 2):S33\u2013S50. doi: 10.1038\/modpathol.3800307","journal-title":"Mod Pathol"},{"issue":"8","key":"240_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.ejca.2013.01.035","volume":"49","author":"A Bois du","year":"2013","unstructured":"du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroder W, Munstedt K, Richter B, Kommoss S, Hauptmann S, Arbeitsgmeinschaft Gynakologische Onkologie Study G (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) study group. Eur J Cancer 49(8):1905\u20131914. doi: 10.1016\/j.ejca.2013.01.035","journal-title":"Eur J Cancer"},{"issue":"3","key":"240_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ygyno.2010.11.016","volume":"120","author":"KK Shih","year":"2011","unstructured":"Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR (2011) Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 120(3):480\u2013484. doi: 10.1016\/j.ygyno.2010.11.016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"240_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejogrb.2009.04.031","volume":"145","author":"MS Lenhard","year":"2009","unstructured":"Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A (2009) Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 145(2):189\u2013194. doi: 10.1016\/j.ejogrb.2009.04.031","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"240_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2005.09.021","volume":"100","author":"R Tinelli","year":"2006","unstructured":"Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A (2006) Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100(1):185\u2013191. doi: 10.1016\/j.ygyno.2005.09.021","journal-title":"Gynecol Oncol"},{"issue":"6","key":"240_CR9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1525-1438.1993.03060349.x","volume":"3","author":"J Kaern","year":"1993","unstructured":"Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO (1993) DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 3(6):349\u2013358","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"240_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ygyno.2005.05.033","volume":"98","author":"A Ayhan","year":"2005","unstructured":"Ayhan A, Guvendag Guven ES, Guven S, Kucukali T (2005) Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 98(3):439\u2013445. doi: 10.1016\/j.ygyno.2005.05.033","journal-title":"Gynecol Oncol"},{"issue":"6","key":"240_CR11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484\u2013486","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"240_CR12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00000478-199611000-00004","volume":"20","author":"JD Seidman","year":"1996","unstructured":"Seidman JD, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20(11):1331\u20131345","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"240_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0002-9440(10)64744-X","volume":"156","author":"WY Chan","year":"2000","unstructured":"Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, Mok SC (2000) Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156(2):409\u2013417. doi: 10.1016\/S0002-9440(10)64744-X","journal-title":"Am J Pathol"},{"issue":"6","key":"240_CR14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","volume":"29","author":"TA Longacre","year":"2005","unstructured":"Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29(6):707\u2013723","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"240_CR15","first-page":"7264","volume":"61","author":"BH Ortiz","year":"2001","unstructured":"Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, Berkowitz RS, Mok SC, Gershenson DM (2001) Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61(19):7264\u20137267","journal-title":"Cancer Res"},{"issue":"4","key":"240_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/pgp.0b013e3180336287","volume":"26","author":"RE Emerson","year":"2007","unstructured":"Emerson RE, Wang M, Liu F, Lawrence WD, Abdul-Karim FW, Cheng L (2007) Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol 26(4):387\u2013394. doi: 10.1097\/pgp.0b013e3180336287","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"240_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/his.12046","volume":"62","author":"R Vang","year":"2013","unstructured":"Vang R, Shih Ie M, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62(1):44\u201358. doi: 10.1111\/his.12046","journal-title":"Histopathology"},{"issue":"3","key":"240_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12253-016-0040-2","volume":"22","author":"D Ates Ozdemir","year":"2016","unstructured":"Ates Ozdemir D, Usubutun A (2016) PAX2, PAX8 and CDX2 expression in metastatic mucinous, primary ovarian mucinous and Seromucinous tumors and review of the literature. Pathol Oncol Res 22(3):593\u2013599. doi: 10.1007\/s12253-016-0040-2","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"240_CR19","first-page":"1489","volume":"53","author":"SC Mok","year":"1993","unstructured":"Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489\u20131492","journal-title":"Cancer Res"},{"issue":"6","key":"240_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/sj.bjc.6603003","volume":"94","author":"VA Heinzelmann-Schwarz","year":"2006","unstructured":"Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94(6):904\u2013913. doi: 10.1038\/sj.bjc.6603003","journal-title":"Br J Cancer"},{"issue":"11","key":"240_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141947","volume":"10","author":"WH Lau","year":"2015","unstructured":"Lau WH, Pandey V, Kong X, Wang XN, Wu Z, Zhu T, Lobie PE (2015) Trefoil factor-3 (TFF3) stimulates de novo angiogenesis in mammary carcinoma both directly and indirectly via IL-8\/CXCR2. PLoS One 10(11):e0141947. doi: 10.1371\/journal.pone.0141947","journal-title":"PLoS One"},{"issue":"3","key":"240_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ajpath.2011.11.022","volume":"180","author":"ARH Ahmed","year":"2012","unstructured":"Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180(3):904\u2013916. doi: 10.1016\/j.ajpath.2011.11.022","journal-title":"Am J Pathol"},{"issue":"2","key":"240_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tem.2007.10.003","volume":"19","author":"JK Perry","year":"2008","unstructured":"Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19(2):74\u201381. doi: 10.1016\/j.tem.2007.10.003","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"240_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ygyno.2013.03.030","volume":"130","author":"P Mhawech-Fauceglia","year":"2013","unstructured":"Mhawech-Fauceglia P, Wang D, Samrao D, Liu S, DuPont NC, Pejovic T (2013) Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. Gynecol Oncol 130(1):174\u2013180. doi: 10.1016\/j.ygyno.2013.03.030","journal-title":"Gynecol Oncol"},{"issue":"5","key":"240_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.peptides.2003.10.019","volume":"25","author":"S Emami","year":"2004","unstructured":"Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C (2004) Trefoil factor family (TFF) peptides and cancer progression. Peptides 25(5):885\u2013898. doi: 10.1016\/j.peptides.2003.10.019","journal-title":"Peptides"},{"issue":"5","key":"240_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13058-014-0429-3","volume":"16","author":"V Pandey","year":"2014","unstructured":"Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, Lobie PE (2014) Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res 16(5):429. doi: 10.1186\/s13058-014-0429-3","journal-title":"Breast Cancer Res"},{"issue":"2","key":"240_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000442710","volume":"90","author":"A Jatoi","year":"2016","unstructured":"Jatoi A, Vierkant RA, Hawthorne KM, Block MS, Ramus SJ, Larson NB, Fridley BL, Goode EL (2016) Clinical and emergent biomarkers and their relationship to the prognosis of ovarian cancer. Oncology 90(2):59\u201368. doi: 10.1159\/000442710","journal-title":"Oncology"},{"issue":"4","key":"240_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/modpathol.2010.215","volume":"24","author":"SE Kalloger","year":"2011","unstructured":"Kalloger SE, Kobel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB (2011) Calculator for ovarian carcinoma subtype prediction. Mod Pathol 24(4):512\u2013521. doi: 10.1038\/modpathol.2010.215","journal-title":"Mod Pathol"},{"issue":"16","key":"240_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"MS LM","year":"2005","unstructured":"LM MS, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180\u20131184. doi: 10.1093\/jnci\/dji237","journal-title":"J Natl Cancer Inst"},{"key":"240_CR30","unstructured":"Kurman RJ, Carcangiu, M.L., Herrington, C.S., Young, R.H (2014) WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer, vol 6."},{"issue":"8","key":"240_CR31","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1007\/s00018-008-8646-5","volume":"66","author":"S Kjellev","year":"2009","unstructured":"Kjellev S (2009) The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci 66(8):1350\u20131369. doi: 10.1007\/s00018-008-8646-5","journal-title":"Cell Mol Life Sci"},{"issue":"14","key":"240_CR32","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1021\/bi00014a033","volume":"34","author":"L Thim","year":"1995","unstructured":"Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK (1995) Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 34(14):4757\u20134764","journal-title":"Biochemistry"},{"issue":"3","key":"240_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2007.05.009","volume":"106","author":"G Walker","year":"2007","unstructured":"Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP (2007) Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 106(3):461\u2013468. doi: 10.1016\/j.ygyno.2007.05.009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"240_CR34","first-page":"655","volume":"21","author":"H Kirikoshi","year":"2002","unstructured":"Kirikoshi H, Katoh M (2002) Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol 21(3):655\u2013659","journal-title":"Int J Oncol"},{"key":"240_CR35","doi-asserted-by":"crossref","unstructured":"Nowak M, Merz C, von Maessenhausen A, Vogel W, Boehm D, Svensson M, Carlsson J, Andren O, Perner S (2015) Role of trefoil factor-3 peptide (TFF3) in prostate cancer progression. Lab invest 95:248a-248a","DOI":"10.1016\/S0959-8049(14)50140-2"},{"issue":"3","key":"240_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433\u2013443. doi: 10.1097\/PAS.0b013e3181cf3d79","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"240_CR37","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1043\/1543-2165-132.11.1753","volume":"132","author":"JD Seidman","year":"2008","unstructured":"Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 132(11):1753\u20131760. doi: 10.1043\/1543-2165-132.11.1753","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"240_CR38","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/00000478-200011000-00001","volume":"24","author":"KR Lee","year":"2000","unstructured":"Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 24(11):1447\u20131464","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"240_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3892\/ijo.2014.2755","volume":"46","author":"K Morito","year":"2015","unstructured":"Morito K, Nakamura J, Kitajima Y, Kai K, Tanaka T, Kubo H, Miyake S, Noshiro H (2015) The value of trefoil factor 3 expression in predicting the longterm outcome and early recurrence of colorectal cancer. Int J Oncol 46(2):563\u2013568. doi: 10.3892\/ijo.2014.2755","journal-title":"Int J Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-017-0240-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T02:56:56Z","timestamp":1569207416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-017-0240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1007\/s12253-017-0240-4","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}